Finding ways to successfully image through light-scattering materials and opaque media is a topic of constant interest for developers of bioimaging platforms, since achieving it will help them to see ...

Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer . If you have the appropriate software installed, you can download article citation data to the ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today ...

CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial Eighty-six ...

Optical phase conjugation (OPC) has emerged as a powerful technique to counteract the deleterious effects of nonlinearity and dispersion in fibre communication systems. By generating a phase-inverted ...

Results from PNEU-PATH demonstrated comparable immune responses following vaccination with Pneumovax 23 in both treatment groups for the 15 serotypes in V114. Merck announced positive topline results ...

Fluorescence imaging is one of the most important research tools in biomedical sciences. However, scattering of light severely impedes imaging of thick biological samples beyond the ballistic regime.

NextCure, Inc. has announced that it has dosed its first patient in a Phase 1 clinical trial for LNCB74, an antibody-drug conjugate targeting B7-H4 for the treatment of multiple cancers. This ...

VANCOUVER, British Columbia, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...

Pneumococcal disease remains a major global health challenge despite the availability of current vaccines This 21-valent pneumococcal conjugate vaccine (PCV21) is the first pneumococcal conjugate ...

Vaxcyte Inc. (NASDAQ:PCVX) on Monday released topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, a 24-valent pneumococcal conjugate ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced positive top-line results from its pivotal U.S. Phase 3 study (NCT04382326) in infants evaluating its 20-valent pneumococcal conjugate ...